Treatment of hematological malignancies with nonmyeloablative, HLA-haploidentical bone marrow transplantation and high dose, post-transplantation cyclophosphamide
- 1 September 2011
- journal article
- review article
- Published by Elsevier in Best Practice & Research Clinical Haematology
- Vol. 24 (3) , 359-368
Abstract
No abstract availableKeywords
Funding Information
- National Cancer Institute
This publication has 59 references indexed in Scilit:
- Improved Survival with Inhibitory Killer Immunoglobulin Receptor (KIR) Gene Mismatches and KIR Haplotype B Donors after Nonmyeloablative, HLA-Haploidentical Bone Marrow TransplantationTransplantation and Cellular Therapy, 2010
- Nonmyeloablative HLA-Haploidentical Bone Marrow Transplantation with High-Dose Posttransplantation Cyclophosphamide: Effect of HLA Disparity on OutcomeTransplantation and Cellular Therapy, 2010
- Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in First Complete RemissionJAMA, 2009
- HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation CyclophosphamideTransplantation and Cellular Therapy, 2008
- Allogeneic hematopoietic cell transplantation for Hodgkin lymphoma: a concise reviewLeukemia & Lymphoma, 2008
- Nonmyeloablative allogeneic hematopoietic stem cell transplant using mismatched/haploidentical donors: A reviewBlood Cells, Molecules, and Diseases, 2008
- Reduced Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation: Current PerspectivesTransplantation and Cellular Therapy, 2007
- Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphomaHuman Immunology, 1990
- Marrow Transplantation from Related Donors Other Than HLA-Identical SiblingsNew England Journal of Medicine, 1985
- Antileukemic Effect of Chronic Graft-versus-Host DiseaseNew England Journal of Medicine, 1981